Friday, July 17, 2009
Destiny Max Clot Detection System Gets US Green Light
Filed under: Pathology
Trinity Biotech out of Co Wicklow, Ireland has received FDA approval to market the Destiny Max haemostasis analyzer. The unit offers high throughput analysis and an option of using optical or micro-mechanical clot detection.
Published features of the Destiny Max:
being the only high throughput instrument on the worldwide market that allows simultaneous and automated measurement of mechanical and optical clot detection, chromogenic and immuno-turbidimetric assays;
best in class graphical user interface and touch screen technology;
the most reliable and novel cap piercing solution on the market. Speed and Throughput
• More than 300 tests/hour
– 350 Tests/hour PT
– 270 Tests/hour PT/APTT
– 195 Tests/hour PT/APTT/FIB
• 100 samples loading capacity
• Maximised walk away time
Optimised Performance
• Cap Piercing – peace of mind
• Result standardisation with TriniVerical
• Multiple measuring wavelengths
• Complete traceability
Ease of Use and Flexibilty
• Ability to choose mechanical or optical clot detection methods
• Continuous loading operation
• Intuitive icon software
• Minimal maintenance
Press release: Trinity Biotech Receives FDA Approval For Destiny Max In The USA...
(0)
examples: <b>Bold</b> <i>Italic</i>
